Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Case Report - Unstable Angina, Coronary Artery Disease, and Cannabis

Version 1 : Received: 24 November 2020 / Approved: 26 November 2020 / Online: 26 November 2020 (11:22:28 CET)

How to cite: Entler, B.; Shaffer, B.; Davis, G.; Incitti, M.; Piper, B. Case Report - Unstable Angina, Coronary Artery Disease, and Cannabis. Preprints 2020, 2020110668. Entler, B.; Shaffer, B.; Davis, G.; Incitti, M.; Piper, B. Case Report - Unstable Angina, Coronary Artery Disease, and Cannabis. Preprints 2020, 2020110668.


Rationale:First discovered in 1990, the endocannabinoid system (ECS) was initially shown to have an intimate relationship with central areas of the nervous system associated with pain, reward, and motivation. Recently, however, the ECS has been extensively implicated in the cardiovascular system with contractility, heart rate, blood pressure, and vasodilation. Emerging data demonstrates modulation of the ECS plays an essential role in cardio metabolic risk, atherosclerosis, and can even limit damage to cardiomyocytes during ischemic events.Patient Concerns:This case describes a 63-year-old male who presented to a primary care physician for a medical cannabis (MC) consult due to unstable angina (UA) not relieved by morphine or cardiac medications; having failed all first- and second-line poly-pharmaceutical therapies. The patient reported frequent, unprovoked, angina and exertional dyspnea.Diagnosis:Having a complex cardiac history, the patient first presented 22 years ago after a suspected myocardial infarction (MI). He re-presented in 2010 and underwent stent placement at that time for inoperable triple-vessel coronary artery disease (CAD) which was identified via percutaneous transluminal coronary angioplasty. UA developed on follow up and, despite medical management over the past 6 years, his UA became progressively debilitating.Interventions and Outcomes:In conjunction with his standard cardiac care, patient had a gradual lessening of UA related pain, including frequency and character, after using an edible form of medical cannabis (MC) (1:1 CBD:THC). Following continued treatment, he ceased long term morphine treatment and describes the pain as no longer crippling. As demonstrated by his exercise tolerance tests, the patient experienced an improved functional capacity and reported an increase in his daily functioning, and overall activity.Lessons:This case uniquely highlights MC in possibly reducing the character, quality, and frequency of UA; while concordantly improving functional cardiac capacity in a patient with CAD. Additional case reports are necessary to verify this.


marijuana; medicinal cannabis (MC); chronic pain (CP); cannabidiol (CBD); tetrahydrocannabinol (THC)


Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.